Hypertrophic scarring (HS) is a common skin injury complication with unmet needs. Verteporfin (VP) should be an ideal HS-targeted therapeutic drug due to its efficient fibrosis and angiogenesis inhibitory abilities. However, its application is restricted by its side effects such as dose-dependent cytotoxicity on normal cells. Herein, the bioadhesive nanoparticles encapsulated VP (VP/BNPs) are successfully developed to attenuate the side effects of VP and enhance its HS inhibition effects by limiting VP releasing slowly and stably in the lesion site but not diffusing easily to normal tissues. VP/BNPs displayed significant inhibition on the proliferation, migration, collagen deposition, and vessel formation of human hypertrophic scar fibroblasts (HSFBs) and dermal vascular endothelial cells (HDVECs). In a rat tail HS model, VP/BNPs treated HS exhibits dramatic scar repression with almost no side effects compared with free VP or VP-loaded non-bioadhesive nanoparticles (VP/NNPs) administration. Further immunofluorescence analysis on scar tissue serial sections validated VP/BNPs effectively inhibited the collagen deposition and angiogenesis by firmly confined in the scar tissue and persistently releasing VP targeted to nucleus Yes-associated protein (nYAP) of HSFBs and HDVECs. These findings collectively suggest that VP/BNPs can be a promising and technically advantageous agent for HS therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/smtd.202301295 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Explorative Study on Knowledge, Attitudes, and Coronavirus Disease 2019 Vaccine Intention among Parents in India.
Am J Trop Med Hyg
January 2025
Department of Pediatrics and Office of Global Health, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
India's National COVID Vaccination Program recommended vaccination of children ages 6-12 years in April 2022. This study assessed vaccine acceptance among mothers to better understand potential barriers and facilitators of national acceptance of pediatric coronavirus disease 2019 (COVID-19) vaccination. Qualitative data were collected through three focus group discussions (FGDs) with mothers who had children younger than 12 years of age; FGD-1 was composed of mothers who worked at a tertiary medical center in India, whereas FGD-2 and FGD-3 were composed of mothers who sought care at urban and rural community health centers.
View Article and Find Full Text PDFPrecision Medicine for High-Risk Gene Fusions in Pediatric AML: a focus on KMT2A, NUP98, and GLIS2 Rearrangements.
Blood
January 2025
Children's Hospital of Philadelphia & University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States.
Robust genetic characterization of paediatric AML has demonstrated that fusion oncogenes are highly prevalent drivers of AML leukemogenesis in young children. Identification of fusion oncogenes associated with adverse outcomes has facilitated risk stratification of patients, although successful development of precision medicine approaches for most fusion-driven AML subtypes have been historically challenging. This knowledge gap has been in part due to difficulties in targeting structural alterations involving transcription factors and in identification of a therapeutic window for selective inhibition of the oncofusion without deleterious effects upon essential wild-type proteins.
View Article and Find Full Text PDFIn unrelated allogeneic hematopoietic cell transplantation (allo-HCT), older and/or HLA-mismatched donors are known risk factors for survival outcomes. In healthy individuals, cytomegalovirus (CMV) seropositivity is associated with impaired adaptive immune systems. We assessed whether the adverse effects of donor risk factors are influenced by the donor CMV serostatus.
View Article and Find Full Text PDFPrehospital Interventions to Reduce Discomfort From Spinal Immobilization in Adult Trauma Patients: A Scoping Review.
J Trauma Nurs
January 2025
Author Affiliations: Department of Community Medicine, Information and Health Decision Sciences, University of Porto, Porto, Portugal (Dr Mota); Health School, Polytechnic Institute of Viseu, Viseu, Portugal (Drs Mota, Santos, and Cunha); Health Sciences Research Unit: Nursing (UICISA: E), Coimbra, Portugal (Drs Mota and Cunha); CINTESIS@RISE - Center for Health Technology and Services Research, University of Porto, Porto, Portugal (Drs Mota and Santos); Academic Clinical Centre of Beiras, Covilhã, Portugal (Drs Mota and Cunha); Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto, Portugal (Drs Melo and Santos); Portugal Centre for Evidence-Based Practice: A Joanna Briggs Institute Centre of Excellence, Coimbra, Portugal (Dr Santos); Hospital São Teotónio, Tondela Viseu Hospital Centre, Viseu, Portugal (Dr Abrantes); Santa Casa da Misericórdia de Seia, Seia, Portugal (Dr Monteiro); and Nursing School of Porto, Porto, Portugal (Dr Santos).
Background: Spinal immobilization, a widely used trauma prehospital intervention, is known to cause discomfort, yet little is known about interventions to reduce this discomfort.
Objective: This scoping review aims to evaluate prehospital interventions to reduce discomfort from spinal immobilization in adult trauma patients.
Method: This scoping review assessed prehospital pharmacological and nonpharmacological interventions to address discomfort from spinal immobilization in adult trauma patients.
l-Asparaginase Immobilized on Nanographene Oxide as an Efficient Nanobiocatalytic Tool for Asparagine Depletion in Leukemia Cells.
Bioconjug Chem
January 2025
Department of Biochemistry, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University in Torun, ul. Lwowska 1, 87-100 Torun, Poland.
l-Asparaginase (l-ASNase) catalyzes the hydrolysis of l-asparagine, leading to its depletion and subsequent effects on the cellular proliferation and survival. In contrast to normal cells, malignant cells that lack asparagine synthase are extremely susceptible to asparagine deficiency. l-ASNase has been successfully employed in treating pediatric leukemias and non-Hodgkin lymphomas; however, its usage in adult patients and other types of cancer is limited due to significant side effects and drug resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!